Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

New molecular targets in the pathophysiology of obesity and available treatment options under investigation

Tools
- Tools
+ Tools

Valsamakis, Georgios, Lois, Konstantinos, Kumar, Sudhesh and Mastorakos, George (2014) New molecular targets in the pathophysiology of obesity and available treatment options under investigation. Clinical Obesity, 4 (4). pp. 209-219. doi:10.1111/cob.12064

Research output not available from this repository, contact author.
Official URL: https://doi.org/10.1111/cob.12064

Request Changes to record.

Abstract

The pharmacotherapy of obesity has historically recorded an overall poor safety and efficacy profile largely because of the complex mechanisms involved in the pathophysiology of obesity. It is hoped that a better understanding of the regulation of body weight will lead us to the development of effective and safer drugs. Recent advances in our understanding of the regulation of energy homeostasis has allowed the design of novel anti-obesity drugs targeting specific molecules crucial for the modulation of energy balance, including drugs that induce satiety, modulate nutrient absorption or influence metabolism or lipogenesis. Almost a decade after the Food and Drug Administration approved the first weight loss medication, it recently approved two novel anti-obesity drugs Belviq (lorcaserin) and Qsymia (topiramate and phentermine), thus signalling the beginning of a new era in the pharmacotherapy of obesity. It is believed that the next generation of weight-loss drugs will be based on combination treatments with gut hormones in a manner that mimics the changes underlying surgically induced weight loss thus introducing the so called ‘bariatric pharmacotherapy’. An in-depth understanding of the interrelated physiological and behavioural effects of these new molecules together with the development of new treatment paradigms is needed so that future disappointments in the field of obesity pharmacotherapy may be avoided.

Item Type: Journal Article
Subjects: Q Science > QP Physiology
R Medicine > RC Internal medicine
R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Body weight -- Regulation, Obesity -- Treatment, Weight loss preparations, Gastrointestinal hormones, Leptin, Serotonin -- Antagonists, Topiramate, Phentermine, Neuropeptide Y, Naltrexone
Journal or Publication Title: Clinical Obesity
Publisher: Wiley
Official Date: August 2014
Dates:
DateEvent
August 2014Published
23 June 2014Available
14 May 2014Accepted
26 August 2013Submitted
Volume: 4
Number: 4
Page Range: pp. 209-219
DOI: 10.1111/cob.12064
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Related URLs:
  • Other

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us